Intersect ENT analyzedSinexus has changed its name to Intersect ENT and the initial focus of Intersect is a bioabsorbable drug eluting stent for treating patients with sinusitis, which is a debilitating condition that affects around 37 million people each year.

Lisa Earnhardt, President and CEO, said that Intersect is a name that suggests their mission to connect drugs and devices to physicians and patients in need.

The company is aiming to offer less invasive forms of treatment that would result in enhanced outcomes and minimized need for systemic drugs such as oral steroids that can lead to severe side effects.